Format

Send to

Choose Destination
See comment in PubMed Commons below
Evid Based Complement Alternat Med. 2011;2011:467134. doi: 10.1093/ecam/nep213. Epub 2011 Feb 14.

Isolation of Bioactive Compounds That Relate to the Anti-Platelet Activity of Cymbopogon ambiguus.

Author information

1
Institute for Glycomics, Gold Coast campus, Griffith University, Queensland, 4222, Australia.
2
Plate-forme d'imagerie dynamique, Institut Pasteur, Paris Cedex 15, France; Genomics Research Centre, Gold Coast campus, Griffith University, Queensland, 4222, Australia.
3
Genomics Research Centre, Gold Coast campus, Griffith University, Queensland, 4222, Australia.

Abstract

Infusions and decoctions of Cymbopogon ambiguus have been used traditionally in Australia for the treatment of headache, chest infections and muscle cramps. The aim of the present study was to screen and identify bioactive compounds from C. ambiguus that could explain this plant's anti-headache activity. A dichloromethane extract of C. ambiguus was identified as having activity in adenosine-diphosphate-induced human platelet aggregation and serotonin-release inhibition bioassays. Subsequent fractionation of this extract led to the isolation of four phenylpropenoids, eugenol, elemicin, eugenol methylether and trans-isoelemicin. While both eugenol and elemicin exhibited dose-dependent inhibition of ADP-induced human platelet serotonin release, only eugenol displayed potent inhibitory activity with an IC50 value of 46.6  μ M, in comparison to aspirin, with an IC50 value of 46.1  μ M. These findings provide evidence to support the therapeutic efficacy of C. ambiguus in the non-conventional treatment of headache and inflammatory conditions.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center